BSH 2017 | The use of CD20 antibodies in CLL patients with Notch1 mutations

Anna Schuh

Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK discusses the use of CD20 antibodies in the treatment of patients that have Notch1 mutations at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Patients with Notch1 mutations do not appear to benefit from combining chemoimmunotherapy with rituximab, a CD20 antibody, findings which have been supported by the CLL-8 study (NCT00281918). Other evidence has shown that patients with Notch1 mutations express less CD20 on their cell surface, explaining the lack of response to rituximab. Approximately 14% of patients have Notch1 mutations, with more having mutations in the non-coding region of Notch1, although rituximab is still routinely used. She states that treatment needs to be altered and improved to reflect the current biological evidence. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.

Share this video